Literature DB >> 23872470

Plasmatic dermatan sulfate and chondroitin sulfate determination in mucopolysaccharidoses.

Nicola Volpi1, Francesca Maccari, Fabio Galeotti, Lucia Zampini, Lucia Santoro, Lucia Padella, Tiziana Galeazzi, Orazio Gabrielli, Giovanni V Coppa.   

Abstract

The evaluation of plasmatic galactosaminoglycans, dermatan sulfate (DS) and chondroitin sulfate (CS) can be helpful in the early identification of MPS patients, also considering that primary storage of one type of GAG can lead to secondary accumulation of other lysosomal substrates. We explore the possibility to determine plasmatic DS and CS in numerous healthy pediatric (and sometimes adult) subjects depending on age and in patients affected by various forms of MPS. A highly sensitive HPLC separation and fluorescence detection was applied for plasma/serum DS and CS determination after a specific enzymatic treatment able to release their constituent disaccharides. DS and CS content decrease significantly with age in controls having high values in the first year (~8 μg/mL). A highly significant decrease was observed for 1-5-year-old (∼-33%) and 5-10-year-old (∼-65%) healthy subgroups. No further decrease was determined showing a stabilization after 5 years of age. MPS I Scheie and Hurler patients showed rather similar DS and CS content significantly higher than controls matched for age. Similarly, MPS II, III and IV subjects all presented significantly higher plasmatic DS and CS content compared to healthy subjects matched for age. The same trend was determined for the only patient affected by MPS VI. Plasmatic DS and CS analyzed by the present procedure may be a useful diagnostic and screening marker for various forms of MPS.
Copyright © 2013 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  0s; 2,4,6tris; 2,4dis; 2,6dis; 4,6dis; 4s; 6s; Blood; CS; Chondroitin sulfate; DBS; DS; Dermatan sulfate; ERT; GAG(s); Glycosaminoglycans; HS; HSCT; KS; MPS; Mucopolysaccharidoses; Plasma; cheratan sulfate; chondroitin sulfate; dermatan sulfate; dried blood spots; enzyme-replacement therapy; glycosaminoglycan(s); hematopoietic stem cell transplantation; heparan sulfate; mucopolysaccharidoses; ΔUA-(1→3)-GalNAc; ΔUA-(1→3)-GalNAc-4,6dis; ΔUA-(1→3)-GalNAc-4s; ΔUA-(1→3)-GalNAc-6s; ΔUA-2s-(1→3)-GalNAc-4,6dis; ΔUA-2s-(1→3)-GalNAc-4s; ΔUA-2s-(1→3)-GalNAc-6s

Mesh:

Substances:

Year:  2013        PMID: 23872470     DOI: 10.1016/j.jpba.2013.06.026

Source DB:  PubMed          Journal:  J Pharm Biomed Anal        ISSN: 0731-7085            Impact factor:   3.935


  4 in total

Review 1.  Glycosaminoglycans detection methods: Applications of mass spectrometry.

Authors:  Francyne Kubaski; Harumi Osago; Robert W Mason; Seiji Yamaguchi; Hironori Kobayashi; Mikako Tsuchiya; Tadao Orii; Shunji Tomatsu
Journal:  Mol Genet Metab       Date:  2016-09-28       Impact factor: 4.797

2.  Evaluation of non-reducing end pathologic glycosaminoglycan detection method for monitoring therapeutic response to enzyme replacement therapy in human mucopolysaccharidosis I.

Authors:  Moin U Vera; Steven Q Le; Alla Victoroff; Merry B Passage; Jillian R Brown; Brett E Crawford; Lynda E Polgreen; Agnes H Chen; Patricia I Dickson
Journal:  Mol Genet Metab       Date:  2019-09-11       Impact factor: 4.797

3.  Glycosaminoglycan signatures in body fluids of mucopolysaccharidosis type II mouse model under long-term enzyme replacement therapy.

Authors:  Francesca Maccari; Laura Rigon; Veronica Mantovani; Fabio Galeotti; Marika Salvalaio; Francesca D'Avanzo; Alessandra Zanetti; Federica Capitani; Orazio Gabrielli; Rosella Tomanin; Nicola Volpi
Journal:  J Mol Med (Berl)       Date:  2022-07-11       Impact factor: 5.606

4.  Glycosaminoglycans from Co-Products of «Scyliorhinus canicula»: Extraction and Purification in Reference to the European Pharmacopoeia Requirement.

Authors:  Nawras Talmoudi; Noureddine Ghariani; Saloua Sadok
Journal:  Biol Proced Online       Date:  2020-01-02       Impact factor: 3.244

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.